** Drug developer Jasper Therapeutics' shares fall ~50% to $8.65
** JSPR says its skin disease drug, briquilimab, met the main goal in the early-stage trial for treating chronic spontaneous urticaria (CSU)
** CSU is a skin condition where red, itchy bumps come and go without a clear reason
** Brokerage William Blair says patients treated with the 180 milligram dose every 8 weeks showed a weaker reduction in disease activity compared with other dose levels
** Brokerage says adverse events are not broken out by dose level, making it difficult to assess the safety profile of specific regimens
** Brokerage says 240 mg and 120 mg doses show strong initial efficacy but lose effectiveness over time, raising concerns about durability and long-term disease control
** All 11 brokerages rate the stock "buy" or higher; their median PT is $69 - LSEG
** JSPR gained 13.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.